Compound reduces joint inflammation offering future hope to those with rheumatoid arthritis

An experimental compound was found to significantly reduce joint inflammation in animal models of rheumatoid arthritis, says research published in Arthritis & Rheumatism.

The study showed the compound, known as SR2211, blocked development of virtually all symptoms of rheumatoid arthritis in mice within the first eight to ten days of treatment. The mice also showed reduced bone and cartilage erosion compared to animals that did not receive treatment.

It works by targeting the nuclear receptor RORγ, a key regulator of TH17 cells, one of a family of white blood cells that play a role in the immune system. TH17 cells have been implicated in many autoimmune diseases including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and lupus.

“Our newest study strongly supports the idea that by targeting the RORγ receptor, we can therapeutically repress inflammation and joint destruction associated with rheumatoid arthritis,” explains biochemist Patrick R Griffin who is involved in the work.

A major benefit of the new compound is that it is taken orally as opposed to being injected; oral medication can be taken daily and stopped immediately to allow the drug to leave the body in the case of a potentially life-threatening infection.